Purpose To develop a predictive pharmacokinetic model for propofol that could inform development of a dosing strategy for the obese population. Methods A prior model that included a nonlinear relationship between clearance (CL) and Total Body Weight (TBW) was re-parameterized with a linear relationship between CL and Lean Body Weight (LBW). The predictive performance of both models was compared and the LBW model used to explore propofol exposure from normal to obese patients. A dosing strategy was evaluated that normalized awakening time across a range of patient weights. Results The predictive performance of the LBW model was similar to the nonlinear TBW model for normal weighted subjects. Simulations in 70–160 kg subjects indicated that d...
Background: Pharmacokinetic (PK) and pharmacodynamic (PD) models are used in target-controlled-infus...
Background: Target-controlled infusion (TCI) systems incorporating pharmacokinetic (PK) or PK-pharma...
Background: Target-controlled infusion (TCI) systems are used to facilitate anesthetic drug administ...
Propofol is an intravenous anaesthetic agent used for the induction and maintenance of general anaes...
Longer awakening times have been observed in obese compared to normal-weight patients when propofol ...
The objective of this study was to develop a pharmacokinetic (PK) model to characterize the influenc...
The objective of this study was to develop a pharmacokinetic (PK) model to characterize the influenc...
BACKGROUND: Obesity is associated with important physiologic changes that can potentially affect the...
Clinicians have observed longer awakening times for obese compared to normal-weight patients when pr...
BACKGROUND: Obesity is associated with important physiologic changes that can potentially affect the...
For most commonly used drugs in morbidly obese patients evidence based dosing guidelines are not ava...
Background: Obesity changes body composition including fat free mass (FFM), regarded as the “pharmac...
BACKGROUND: Pharmacokinetic (PK) models are used to predict drug concentrations for infusion regimen...
BACKGROUND: Pharmacokinetic (PK) models are used to predict drug concentrations for infusion regimen...
Background: Pharmacokinetic (PK) and pharmacodynamic (PD) models are used in target-controlled-infus...
Background: Target-controlled infusion (TCI) systems incorporating pharmacokinetic (PK) or PK-pharma...
Background: Target-controlled infusion (TCI) systems are used to facilitate anesthetic drug administ...
Propofol is an intravenous anaesthetic agent used for the induction and maintenance of general anaes...
Longer awakening times have been observed in obese compared to normal-weight patients when propofol ...
The objective of this study was to develop a pharmacokinetic (PK) model to characterize the influenc...
The objective of this study was to develop a pharmacokinetic (PK) model to characterize the influenc...
BACKGROUND: Obesity is associated with important physiologic changes that can potentially affect the...
Clinicians have observed longer awakening times for obese compared to normal-weight patients when pr...
BACKGROUND: Obesity is associated with important physiologic changes that can potentially affect the...
For most commonly used drugs in morbidly obese patients evidence based dosing guidelines are not ava...
Background: Obesity changes body composition including fat free mass (FFM), regarded as the “pharmac...
BACKGROUND: Pharmacokinetic (PK) models are used to predict drug concentrations for infusion regimen...
BACKGROUND: Pharmacokinetic (PK) models are used to predict drug concentrations for infusion regimen...
Background: Pharmacokinetic (PK) and pharmacodynamic (PD) models are used in target-controlled-infus...
Background: Target-controlled infusion (TCI) systems incorporating pharmacokinetic (PK) or PK-pharma...
Background: Target-controlled infusion (TCI) systems are used to facilitate anesthetic drug administ...